公开(公告)号：US12209125B2

公开(公告)日：2025-01-28

申请号：US16755082

申请日：2018-03-09

Applicant: CELLECTIS

Inventor： Brian Busser ,  Philippe Duchateau ,  Alexandre Juillerat ,  Laurent Poirot ,  Julien Valton

IPC: A61K35/00 ,  A61K39/00 ,  C07K16/28 ,  C07K16/30 ,  C12N5/0783 ,  C12N5/10

Abstract: The invention pertains to the field of adaptive cell immunotherapy. It provides with the genetic insertion of exogenous coding sequence(s) that help the immune cells to direct their immune response against infected or malignant cells. These exogenous coding sequences are more particularly inserted under the transcriptional control of endogenous gene promoters that are sensitive to immune cells activation. Such method allows the production of safer immune primary cells of higher therapeutic potential.

公开(公告)号：US11873511B2

公开(公告)日：2024-01-16

申请号：US16340222

申请日：2017-10-19

Applicant: CELLECTIS

Inventor： Brian Busser ,  Philippe Duchateau ,  Alexandre Juillerat ,  Laurent Poirot ,  Julien Valton

IPC: C12N5/078 ,  A61K35/17 ,  C12N15/90 ,  C12N9/22 ,  C12N5/0783

CPC classification number: C12N5/0638 ,  A61K35/17 ,  C12N9/22 ,  C12N15/907 ,  C12N2510/00 ,  C12N2750/14143 ,  C12N2830/008

Abstract: The invention pertains to the field of adaptive cell immunotherapy. It provides with the genetic insertion of exogenous coding sequence(s) that help the immune cells to direct their immune response against infected or malignant cells. These exogenous coding sequences are more particularly inserted under the transcriptional control of endogenous gene promoters that are sensitive to immune cells activation. Such method allows the production of safer immune primary cells of higher therapeutic potential.

公开(公告)号：US12221478B2

公开(公告)日：2025-02-11

申请号：US16755093

申请日：2018-04-16

Applicant: CELLECTIS

Inventor： Brian Busser ,  Philippe Duchateau ,  Alexandre Juillerat ,  Laurent Poirot ,  Julien Valton ,  Mohit Sachdeva

IPC: C07K16/28 ,  A61K39/00 ,  C07K16/30 ,  C12N5/0783 ,  C12N5/10

Abstract: The invention pertains to the field of adaptive cell immunotherapy. It provides with the genetic insertion of exogenous coding sequence(s) into genetically engineered immune cells to prevent cytokine release syndrome to arise during the course of cell therapy. These exogenous coding sequences are more particularly soluble human polypeptides placed under the transcriptional control of endogenous gene promoters that are sensitive to immune cells activation. Such method allows the production of safer immune primary cells of higher therapeutic potential.